X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production

Orchidée Filipe-Santos1, Jacinta Bustamante, Margje H Haverkamp

  • 1Laboratory of Human Genetics of Infectious Diseases, University of Paris René Descartes-Institut National de la Santé et de la Recherche Médicale (INSERM) U 550, Necker Medical School, Paris, France.

Insights

X-linked recessive Mendelian susceptibility to mycobacterial diseases (MSMD) is caused by mutations in the NEMO gene. These mutations impair T cell-dependent IL-12 production, crucial for immunity against mycobacteria.

Area of Science:

  • Immunology
  • Genetics
  • Molecular Biology

Background:

  • Mendelian susceptibility to mycobacterial diseases (MSMD) is a rare genetic disorder characterized by impaired immunity to mycobacteria.
  • While autosomal forms of MSMD are linked to defects in IL-12-IFN-gamma pathways, the genetic basis of X-linked recessive (XR)-MSMD remained elusive.

Observation:

  • Researchers identified mutations in the leucine zipper (LZ) domain of the NF-kappaB essential modulator (NEMO) gene in three families with XR-MSMD.
  • Patients' monocytes showed a defect in T cell-dependent IL-12 production, leading to reduced IFN-gamma secretion by T cells.
  • This impairment stemmed from a specific defect in NEMO and NF-kappaB/c-Rel-mediated CD40 signaling.

Findings:

  • Two novel mutations in the NEMO LZ domain were identified as the first genetic cause of XR-MSMD.
  • The identified mutations specifically disrupted CD40 signaling required for IL-12 induction by monocytes and dendritic cells.
  • Crucially, other NF-kappaB activating pathways, CD40-dependent B cell functions, and costimulatory molecule expression remained unaffected.

Implications:

  • These findings establish the genetic etiology of XR-MSMD and highlight the critical role of NEMO in this specific immune pathway.
  • The study underscores the importance of the NEMO/NF-kappaB/c-Rel pathway in CD40-mediated IL-12 induction for human mycobacterial immunity.
  • Understanding these genetic defects opens avenues for improved diagnostics and potential therapeutic strategies for patients with XR-MSMD.